1684.00DKK-1.66%Mkt Cap: 103.39B DKKP/E: 20.12Last update: 2026-05-13
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with rel…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)20.12
P/E (Forward)15.62
PEG1.75
P/B2.78
P/S26.50
EV/EBITDA80.60
EV/Revenue27.48
EPS (TTM)83.69
EPS (Forward)107.80
Cash Flow & Leverage
FCF Yield0.80%
FCF Margin21.29%
Operating CF1.19B DKK
CapEx (TTM)55.00M DKK
Net Debt/EBITDA2.88
Net Debt3.83B DKK
Technical
SMA 501727.57 (-2.5%)
SMA 2001864.60 (-9.7%)
Beta0.69
S&P 52W Chg24.23%
Avg Vol (30d)136.81K
Avg Vol (10d)203.73K
Technical Indicators
RSI (14)44.9
MACD-18.5494
MACD Signal-16.3832
MACD Hist.-2.1661
BB Upper1814.94 DKK
BB Middle1721.78 DKK
BB Lower1628.61 DKK
BB Width10.82%
ATR (14)58.03 DKK
Vol Ratio (20d)1.02x
52W Range
1204.5046% of range2257.00
52W High2257.00 DKK
52W Low1204.50 DKK
Profitability
Gross Margin93.60%
EBITDA Margin34.09%
Profit Margin25.89%
Oper. Margin25.11%
ROE16.47%
ROA7.48%
Revenue Growth25.30%
Earnings Growth-72.80%
Balance Sheet
Debt/Equity0.93
Current Ratio2.18
Quick Ratio2.17
Book Value/Sh604.70 DKK
Cash/Share24.84 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.61.39M
Float60.66M
Insiders0.00%
Institutions44.96%
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)2313.13 DKK
Target Range1400.00 DKK – 3000.00 DKK
# Analysts15
Company
Market Cap103.39B DKK
Enterprise Value107.20B DKK
Revenue (TTM)3.90B DKK
Gross Profit3.48B DKK
Net Income (TTM)963.00M DKK
Revenue/Share62.93 DKK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3.1K
Last Price1684.00 DKK
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—